DEXONE 4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXONE 4 (DEXONE 4).
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
| Metabolism | Primarily hepatic via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. |
| Excretion | Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%) |
| Half-life | Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions |
| Protein binding | 77% bound primarily to corticosteroid-binding globulin (CBG) and albumin |
| Volume of Distribution | 0.6-1.0 L/kg; indicates extensive distribution into total body water, with higher volume in obese patients |
| Bioavailability | Oral: 80-90%; Intramuscular: 80-100% |
| Onset of Action | Oral: 1-2 hours; Intravenous: immediate (minutes); Intramuscular: 1-2 hours |
| Duration of Action | Duration of metabolic effects: 24-36 hours (based on hypothalamic-pituitary-adrenal axis suppression); clinical duration varies with dose and condition |
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based adjustment required; use with caution in severe renal impairment due to fluid retention. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%. |
| Pediatric use | 0.02–0.3 mg/kg/day or 0.6–9 mg/m²/day in divided doses every 6–12 hours. |
| Geriatric use | Initiate at lowest effective dose; monitor for osteoporosis, hyperglycemia, and fluid retention; adjust dose based on response and tolerance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEXONE 4 (DEXONE 4).
| Breastfeeding | Dexamethasone is excreted in breast milk in low amounts. The M/P ratio is approximately 0.15-0.2. At maternal doses ≤ the equivalent of prednisone 20 mg/day, infant exposure is negligible. Use with caution, especially at higher doses or prolonged therapy. |
| Teratogenic Risk | First trimester: Corticosteroids are associated with a small increased risk of orofacial clefts (absolute risk increase ~0.1-0.2%). Second/third trimester: Chronic use may cause fetal adrenal suppression, growth restriction, and oligohydramnios. Risk is dose- and duration-dependent. |
■ FDA Black Box Warning
Corticosteroids may cause dose-dependent suppression of the hypothalamic-pituitary-adrenal (HPA) axis, leading to adrenal insufficiency or crisis upon withdrawal or stress. Avoid abrupt discontinuation.
| Serious Effects |
Systemic fungal infections; known hypersensitivity to dexamethasone; live virus vaccinations (concurrent use); idiopathic thrombocytopenic purpura (IM administration).
| Precautions | Increased risk of infections; masking of infection signs; gastrointestinal perforation; osteoporosis; HPA axis suppression; growth suppression in children; psychiatric disturbances; ocular effects (glaucoma, cataracts); hypertension; congestive heart failure; thromboembolism; anaphylactoid reactions. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, blood glucose, and signs of infection. For prolonged therapy, fetal growth ultrasound and amniotic fluid volume assessment are recommended. Monitor newborn for signs of adrenal suppression if used near term. |
| Fertility Effects | No direct evidence of impaired fertility in humans. Corticosteroids may affect ovulation and spermatogenesis at high doses, but clinically significant effects are unlikely. |